Cedilla Therapeutics

We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stabilize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures. Interested in helping us build a great company? We are focused on building an amazing organization and have needs across a spectrum of capabilities. We do not like to box people in with job descriptions (though we have them if you want them); we would rather focus on your skills and what you will bring to our phenomenal team. We hire passionate people who want to do important work.